Healthcare Industry News: Immunomedics
News Release - May 13, 2015
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical DevelopmentNew Executive Brings Wealth of Experience and Impressive Track Record as Company Approaches Pivotal Trial
NEW YORK, NY--(Healthcare Sales & Marketing Network) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Jeng-Dar Yang, Ph.D. to the position of Vice President of Pharmaceutical Development effective May 4, 2015. Dr. Yang brings with him 23 years of biotechnology experience in increasingly senior roles.
"We are delighted to add Jeng-Dar's breadth and width of biologics product development experience to the Actinium team. He brings to Actinium a proven track record of successful product development spanning monoclonal antibody and recombinant proteins production from cell line development to purification to conjugation," said Kaushik J. Dave, President and CEO of Actinium Pharmaceuticals. "In addition, Jeng-Dar has significant regulatory experience. All of these are key skills as we ramp up our preparations for a pivotal trial."
"I am very excited to join the Actinium organization," said Dr. Yang. "With two very promising clinical stage products, Actinium is on the cusp of significant breakthroughs in the field I have been working in for almost quarter of the century. I am thrilled to have an opportunity to contribute in a meaningful way."
Dr. Yang joins Actinium Pharmaceuticals from Immunomedics Inc. where he was the Executive Director, Cell Culture Production. As part of the CMC leadership team at Immunomedics, he was in charge of the Clinical Production overseeing all aspects of upstream manufacturing of late stage biological drug candidates and achieved close to 100% success rate for cGMP bioreactor production. Prior to joining Immunomedics, Dr. Yang worked in upstream and downstream process development for early-stage products at Enzon, Inc. He received his Ph.D. in Chemical Engineering from University of Maryland, College Park and his BS in Chemical Engineering from Tsing-Hua University, Taiwan.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Source: Actinium Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.